Over the past 10 years, this proportion remained unchanged in men and showed an increasing trend in women.
← all excerpts
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.
2
—
—
The sentences
The HIJ-PROPER study 341) of ACS did not statistically prove the benefit of active LDL-C lowering therapy with ezetimibe compared to pitavastatin alone, but showed a trend toward the reduction of ASCVD, suggesting that the management of LDL-C in secondary prevention is also “the lower, the better.